Scarica l'app Stockscreener
6.38
1.59%
0.10
Dopo l'orario di chiusura:
6.38
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMEA Giù?
Forum
Previsione
Biomea Fusion Inc Borsa (BMEA) Ultime notizie
HC Wainwright Reiterates Buy Rating for Biomea Fusion (NASDAQ:BMEA) - MarketBeat
Late-Breaker Oral Presentation Showing New Analysis from - GlobeNewswire
Biomea Fusion's Diabetes Drug Shows 1.23% HbA1c Drop in Key Patient Group | BMEA Stock News - StockTitan
(BMEA) Investment Report - Stock Traders Daily
We're A Little Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate - Yahoo Finance
How To Trade (BMEA) - Stock Traders Daily
Biomea Fusion, Inc. Reveals Preclinical Data on Icovamenib and BMF-650 in Recent SEC Filing - Defense World
Biomea Fusion's SWOT analysis: clinical hold clouds diabetes drug stock outlook - Investing.com India
Biomea Fusion FY2024 EPS Estimate Raised by HC Wainwright - Defense World
HC Wainwright Forecasts Increased Earnings for Biomea Fusion - MarketBeat
Biomea Fusion (NASDAQ:BMEA) Stock Price Expected to Rise, Piper Sandler Analyst Says - Defense World
Biomea Fusion’s (BMEA) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
BMEABiomea Fusion, Inc. Latest Stock News & Market Updates - StockTitan
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Biomea Fusion stock PT raised by Piper Sandler, citing pipeline potential - Investing.com Australia
HC Wainwright Reiterates "Buy" Rating for Biomea Fusion (NASDAQ:BMEA) - MarketBeat
Biomea Fusion Unveils Promising Diabetes Treatment Innovations - TipRanks
Biomea Fusion Reports Q3 2024 Financial Results - MSN
Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate - GlobeNewswire
Barclays Forecasts Strong Price Appreciation for Biomea Fusion (NASDAQ:BMEA) Stock - MarketBeat
Biomea Awaits 2 Data Readouts Of Diabetes StudiesCan The Stock Get Its Mojo Back? - RTTNews
Biomea Fusion (NASDAQ:BMEA) Announces Earnings Results - MarketBeat
Biomea Fusion price target raised to $11 from $9 at Barclays - TipRanks
Biomea Fusion reports Q3 EPS (91c), consensus (95c) - TipRanks
Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights - The Manila Times
Biomea Fusion options imply 6.1% move in share price post-earnings - TipRanks
Biomea Fusion, Inc. (NASDAQ:BMEA) Given Average Rating of "Buy" by Brokerages - MarketBeat
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Rating of “Buy” from Brokerages - Defense World
(BMEA) Technical Data - Stock Traders Daily
Biomea Fusion shares maintain Buy rating from H.C. Wainwright By Investing.com - Investing.com Australia
Biomea Fusion's (BMEA) Buy Rating Reiterated at HC Wainwright - MarketBeat
Biomea Fusion shares maintain Buy rating from H.C. Wainwright - Investing.com
Exchange Traded Concepts LLC Acquires 8,079 Shares of Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Biomea Fusion's icovamenib gets global and US naming approval - Investing.com India
Biomea Fusion's icovamenib gets global and US naming approval By Investing.com - Investing.com South Africa
Biomea Fusion announces approval of ‘icovamenib’ as INN for BMF-219 - TipRanks
Biomea Fusion Announces Approval of 'icovamenib” as International Nonproprietary Name for BMF-219 - The Manila Times
Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219 - GlobeNewswire
Biomea Fusion (NASDAQ:BMEA) & Acrivon Therapeutics (NASDAQ:ACRV) Financial Survey - Defense World
(BMEA) Investment Analysis and Advice - Stock Traders Daily
Griffin Asset Management Inc. Purchases 57,180 Shares of Biomea Fusion, Inc. (NASDAQ:BMEA) - MarketBeat
Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-21 - The Manila Times
Marshall Wace LLP Sells 3,900 Shares of Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Squarepoint Ops LLC Takes Position in Biomea Fusion, Inc. (NASDAQ:BMEA) - MarketBeat
Investigation Launched into Biomea Fusion Securities - Bit Perfect Solutions
0.93%
3.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):